Aspirin was recommended in the past as an alternative to oral anticoagulation for the prevention of thromboembolism in patients with atrial fibrillation (AF) and a CHA2DS2-VASc score of 1 [1]. The supposed beneficial effect of aspirin compared to placebo/control was supported by a single randomized controlled trial (RCT) which was prematurely terminated, with marked internal heterogeneity for the aspirin effect between anticoagulation-eligible and anticoagulation-ineligible patients [2,3].
